Seminar Held on Insurance Coverage Strategy for Medical Devices in Light of the 2026 Medical Fee Revision – PR TIMES

News Highlights

A seminar was held on insurance coverage strategies for medical devices, looking ahead to the FY2026 medical fee revision. Key takeaways include mid-to-long-term management and succession strategies considering the revision cycle, economies of scale through group formation, and utilization of tax schemes including transitions to specific or social medical corporations.

M&A Medical Editorial Department’s Perspective

The FY2026 medical fee revision will compel medical device manufacturers to reconsider their insurance coverage strategies. In particular, medical institutions will be forced to consider more advanced management and succession strategies, such as group formation to benefit from “economies of scale” and changes in corporate status with tax incentives in mind. For example, the trend of multiple clinics or small-to-medium-sized hospitals integrating to jointly introduce and operate high-cost medical devices, thereby dispersing the burden of maintaining individual facility standards and capital investment, may accelerate. This could become a powerful driver for M&A and business restructuring not only for addressing a lack of successors but also for strengthening the management base and improving profitability.

Points Raised by This News

• The FY2026 medical fee revision will impact insurance coverage strategies for medical devices.
• Medical institutions face the need for mid-to-long-term management and succession strategies that consider the revision cycle.
• Economies of scale through group formation (maintaining facility standards, dispersing capital investment burden) will be emphasized.
• Utilization of tax schemes, including transitions to specific or social medical corporations, will be incorporated into management strategies.

Practical Questions Arising from This News

• What specific medical devices do you think will be most affected in terms of insurance coverage by this medical fee revision?
• What are the specific advantages and disadvantages of group formation for clinics?
• For which medical institutions is transitioning to a specific or social medical corporation a viable option?

If You Feel “Should I Consult Too?”

Medical institution managers considering responses to the FY2026 medical fee revision, particularly group formation or changes in corporate status with future capital investment and management base strengthening in mind, will benefit from early consultation with experts in M&A and business succession strategies. Let’s aim for sustainable growth in the rapidly changing healthcare industry by aligning your institution’s current status with its future vision and considering the optimal scheme.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as a certified M&A support institution by the Small and Medium Enterprise Agency, with a full success fee system. We handle consultations with strict confidentiality. Free consultations are available here.